280 Efficacy of Rifaximin for Sibo Treatment in Ibs Children

  • Giorgio V
  • D'Andrea V
  • Coccia P
  • et al.
N/ACitations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Our previous study suggested a significant epidemiologic association between SIBO (Small Intestinal Bacterial Overgrowth) and IBS (Irritable Bowel Syndrome) in childhood. Rifaximin has already been successfully used in adults with SIBO and IBS. Aim: To assess the SIBO prevalence and symptoms improvement in IBS children after treatment with Rifaximin. Study design: 43 (mean age 9,5 ys) consecutive children affected by IBS according to Rome II criteria were enrolled. The control population (n = 28, mean age 10 ys) consisted of healthy subjects without IBS symptoms, similar to patients for age, sex, and social background. All subjects underwent lactulose/methane breath test (LBT) to assess SIBO before and one month after the treatment with Rifaximin 600 mg daily. All IBS pts filled out a Visual Analogic Scale (VAS) score to evaluate symptoms (abdominal pain, constipation, diarrhoea, bloating, flatulence) at time zero and 1 month after the treatment. Results: The prevalence of abnormal LBT result was significantly higher in patients with IBS than controls (65%, 28/43 vs 7%, 2/28, p<0.05). One month after the treatment 18 pts had a negative LBT while 10 stayed positive (64%, 18/28 vs 36%, 10/28, p<0.05). In IBS pts VAS score was significantly higher in SIBO positive than SIBO negative children. One month after treatment VAS score was significantly lower in eradicated than non-eradicated pts. Conclusions: Rifaximin is safe and seems to be effective in SIBO eradication and symptoms improvement of IBS pts. Other placebo-controlled interventional studies with antibiotics used to treat bacterial overgrowth are warranted to verify the real impact of the disease on IBS symptoms

Cite

CITATION STYLE

APA

Giorgio, V., D’Andrea, V., Coccia, P., Filoni, S., Rendeli, C., & Fundarò, C. (2010). 280 Efficacy of Rifaximin for Sibo Treatment in Ibs Children. Pediatric Research, 68, 144–144. https://doi.org/10.1203/00006450-201011001-00280

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free